Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure S2 ARK5/NUAK1 Aurora A PKN1/PRK1 CK1g2 PAK5 HPK1/MAP4K1 ABL1

Published byZdeňka Vávrová Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure S2 ARK5/NUAK1 Aurora A PKN1/PRK1 CK1g2 PAK5 HPK1/MAP4K1 ABL1"— Presentation transcript:

1 Figure S2 ARK5/NUAK1 Aurora A PKN1/PRK1 CK1g2 PAK5 HPK1/MAP4K1 ABL1 FER LRRK2 TAK1 MLK2/MAP3K10 MLK1/MAP MLK3/MAP3 JAK3 TNK1 FLT3 ERBB4/HER4 ERBB2/HER2 EGFR FMS RET TRKA TRKB TRKC SYK YES/YES1 LCK BLK TEC TXK BTK BMX/ETK < 1% 1~10% 10~20% % Activity at 1µM of AC0010 Figure S2. AC0010 kinase profiling. Graphical representation of AC0010 selectivity against a panel of 349 kinases, based on the phylogenetic tree of human kinases. Among selected kinase targets with greater than 80% inhibition, they are JAK3, BLK and 5 TEC family members.

Download ppt "Figure S2 ARK5/NUAK1 Aurora A PKN1/PRK1 CK1g2 PAK5 HPK1/MAP4K1 ABL1"

Similar presentations

1. 2 Figure 7.1: A Graphical Representation of “Arbitraging the Zero-coupon Bond Price Curve” Time (T) Prices P(0,T) ||||01234||||01234 1 X FMFM F=M X.

1. 2 Figure 7.1: A Graphical Representation of “Arbitraging the Zero-coupon Bond Price Curve” Time (T) Prices P(0,T) ||||01234|||| X FMFM F=M X.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and Without JAK2 Mutation Alessandro M. Vannucchi Section of Hematology, University.

Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and Without JAK2 Mutation Alessandro M. Vannucchi Section of Hematology, University.
Computational Analyses of Human Kinome against EGFR-TKIs using Homology Modeling and Molecular Docking Approaches Orathai Sawatdichaikul Institute of Food.

Computational Analyses of Human Kinome against EGFR-TKIs using Homology Modeling and Molecular Docking Approaches Orathai Sawatdichaikul Institute of Food.
Protein Domains That Interact with Receptor Tyrosine Kinases: Structural Aspects Ming-Ming Zhou, Ph.D. MSSM Department of Pharmacology Course on “Cell.

Protein Domains That Interact with Receptor Tyrosine Kinases: Structural Aspects Ming-Ming Zhou, Ph.D. MSSM Department of Pharmacology Course on “Cell.
CLASS DIAGRAM. What is a class diagram? Imagine you were given a task of drawing a family tree. The steps you would take would be: What is a class diagram?

CLASS DIAGRAM. What is a class diagram? Imagine you were given a task of drawing a family tree. The steps you would take would be: What is a class diagram?
January 5  8.  Our new unit will be over representing data (graphs). Copy the questions and answer them using full sentences:  Where can data be found.

January 5  8.  Our new unit will be over representing data (graphs). Copy the questions and answer them using full sentences:  Where can data be found.
CELLULAR KINASE MTO pTrkA (Tyr490) and (Tyr674/675)

CELLULAR KINASE MTO pTrkA (Tyr490) and (Tyr674/675)
Overall (regardless of smoking Hx) Prior or current smoking Hx

Overall (regardless of smoking Hx) Prior or current smoking Hx
The Center for Personalized Diagnostics: Past, Present, and FUTURE

The Center for Personalized Diagnostics: Past, Present, and FUTURE
From: Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.

From: Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.
From: Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.

From: Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Institute of Biomedical & Genetic Engineering (IBGE)

Institute of Biomedical & Genetic Engineering (IBGE)
Supporting Figure S4 (A) (B) (C) LOC_Os03G04630 LOC_Os03G04640

Supporting Figure S4 (A) (B) (C) LOC_Os03G04630 LOC_Os03G04640
Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 

Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 
Unrooted phylogenetic tree showing the relationship between the human SLC2A gene family for all 14 members created using PHYLIP 3.6 softwareDistance between.

Unrooted phylogenetic tree showing the relationship between the human SLC2A gene family for all 14 members created using PHYLIP 3.6 softwareDistance between.
Featured Inhibitors for October-BOC Sciences

Featured Inhibitors for October-BOC Sciences
SIG Projects Suggested Project Idea: Model recruitment of signaling proteins (with SH2 domains) to a receptor tyrosine kinase (RTK) in different cell.

SIG Projects Suggested Project Idea: Model recruitment of signaling proteins (with SH2 domains) to a receptor tyrosine kinase (RTK) in different cell.
Figure S1, FGFR2 copy gain and overexpression in H716 cells A

Figure S1, FGFR2 copy gain and overexpression in H716 cells A

Similar presentations

Ads by Google